Compare GSK plc (GSK) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Global X Robo Global Robotics & Automation ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Global X Robo Global Robotics & Automation ETF trades at $81.26 (market cap $2.06B). The key difference: GSK plc is far larger — about 44.6× Global X Robo Global Robotics & Automation ETF's market cap, and GSK plc pays a 3.9% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Global X Robo Global Robotics & Automation ETF for 36 Days on average.
| GSK | ROBO | |
|---|---|---|
Market Cap | $91.88B | $2.06B |
Volume | 7,730,529 | 148,111 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $90.34 |
52-Week Low | $43.24 | $63.04 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
ROBO trades at $81.26, down 0.68% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong institutional interest in robotics and AI themes, with recent news highlighting accelerating adoption across manufacturing, healthcare, and military applications. Financial ratios are unavailable in the current dataset.
The robotics sector offers long-term growth potential amid labor shortages and AI integration, though high RSI levels suggest near-term overbought conditions. Key risks include valuation concerns and sector competition, while analyst coverage remains favorable for diversified robotics exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
